The Department of Energy named Fishers-based American Resources among five projects in a $75M pilot to recover rare earths from coal, spotlighting central Indiana’s refining plans.

The FDA tapped seven companies — including Eli Lilly and Regeneron — for a PreCheck pilot to speed reviews of new U.S. drug plants. The cohort includes big pharma and specialized CDMOs.

IU Health opened an FDA-cleared 3D print studio at Methodist Hospital, producing patient-specific anatomical models for surgical planning and training.

Riley Hospital at IU Health used cryopreserved marrow from a deceased donor in a world‑first pediatric transplant, putting a 14‑year‑old with leukemia into remission.

A Baylor‑led consortium's AllFaith Benchmark finds major language models often omit religious perspectives in ethics answers and show conversion biases. The work is open‑sourced for developers and scholars.

A 12‑year‑old Center Grove student is the first in Indiana to receive an FDA‑approved gene therapy at Riley, a treatment that could end her monthly transfusions.

Eli Lilly says its experimental drug retatrutide produced near‑surgical levels of weight loss in late‑stage trials, but analysts note higher side effects and access questions.

A new Crossroads Academic Medical Institute launched in Indianapolis to coordinate clinical training across the state and widen access to care. Universities and hospital systems will share sites and curricula.

Sam Schmidt converted the old Five Seasons club into a 114,000‑sq‑ft DRIVEN Neuro Recovery Center in Carmel, pairing deep‑water therapy, robotic gait trainers and nonprofit care. The campus aims to offer long‑term rehab beyond typical insurance limits.

Mounjaro's Q1 sales topped Keytruda, lifting Lilly's revenue and reshaping the blockbuster drug ranking.

Gov. Mike Braun and business leaders launched IN AI, a statewide hub and roadshows to help Hoosier employers use human-centered AI to increase productivity and wages.

Eli Lilly agreed to buy Ajax Therapeutics for up to $2.3 billion, taking on a Cambridge biotech's experimental Type II JAK2 drug for myelofibrosis with data due in 2026.

Carmel will pilot Qwake’s C‑THRU AR helmets this summer — 16 helmets and four command tablets in a three‑year, $375K program funded with help from the Heroes Club.